{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:49:50Z","timestamp":1791578990993,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03786-y","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:56:14Z","timestamp":1791532574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4620-3580","authenticated-orcid":false,"given":"Amie","family":"Padhiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4671-7600","authenticated-orcid":false,"given":"Colin","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3831-6270","authenticated-orcid":false,"given":"Mathilde","family":"Puls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-6652","authenticated-orcid":false,"given":"Annie","family":"Berkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0087-3798","authenticated-orcid":false,"given":"Oliver","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8545-5873","authenticated-orcid":false,"given":"Harneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-6955","authenticated-orcid":false,"given":"Harold","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0891-2234","authenticated-orcid":false,"given":"Linda","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"3786_CR1","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","volume":"133","author":"F Alwan","year":"2019","unstructured":"Alwan F, Vendramin C, Liesner R, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood. 2019;133:1644\u201351.","journal-title":"Blood"},{"key":"3786_CR2","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020.","journal-title":"Nat Rev Dis Primers"},{"key":"3786_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103365","volume":"12","author":"K Sakai","year":"2023","unstructured":"Sakai K, Matsumoto M. Clinical manifestations, current and future therapy, and long-term outcomes in congenital thrombotic thrombocytopenic purpura. J Clin Med. 2023;12:3365.","journal-title":"J Clin Med"},{"key":"3786_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175152","volume":"13","author":"RJ Shaw","year":"2024","unstructured":"Shaw RJ, Abrams ST, Badu S, Toh CH, Dutt T. The highs and lows of ADAMTS13 activity. J Clin Med. 2024;13:5152.","journal-title":"J Clin Med"},{"key":"3786_CR5","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2023-189416","volume":"142","author":"P Coppo","year":"2023","unstructured":"Coppo P, Scully M, Kremer Hovinga JA, et al. Clinical outcomes of congenital thrombotic thrombocytopenic purpura: a multinational chart review study. Blood. 2023;142:4006.","journal-title":"Blood"},{"key":"3786_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.17560","volume":"194","author":"K Sakai","year":"2021","unstructured":"Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol. 2021;194:444\u201352.","journal-title":"Br J Haematol"},{"key":"3786_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ajh.23527","volume":"88","author":"F Peyvandi","year":"2013","unstructured":"Peyvandi F, Mannucci PM, Valsecchi C, Pontiggia S, Farina C, Retzios AD. ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates. Am J Hematol. 2013;88:895\u20138.","journal-title":"Am J Hematol"},{"key":"3786_CR8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2314793","volume":"390","author":"M Scully","year":"2024","unstructured":"Scully M, Antun A, Cataland SR, et al. Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura. N Engl J Med. 2024;390:1584\u201396.","journal-title":"N Engl J Med"},{"key":"3786_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","volume":"203","author":"M Scully","year":"2023","unstructured":"Scully M, Rayment R, Clark A, et al. A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol. 2023;203:546\u201363.","journal-title":"Br J Haematol"},{"key":"3786_CR10","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","volume":"23","author":"XL Zheng","year":"2025","unstructured":"Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23:3711\u201332.","journal-title":"J Thromb Haemost"},{"key":"3786_CR11","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/blood.2020009801","volume":"137","author":"E Tarasco","year":"2021","unstructured":"Tarasco E, Butikofer L, Friedman KD, et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021;137:3563\u201375.","journal-title":"Blood"},{"key":"3786_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. Adzynma Intravenous 1500 [prescribing infomation]. 2024. https:\/\/www.pmda.go.jp\/files\/000272019.pdf. Accessed 22 Nov 2025."},{"key":"3786_CR13","unstructured":"ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for injection, for intravenous use [prescribing information]. 2023. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-and-Patient-Information-ADZYNMA.pdf. Accessed 22 Nov 2025."},{"key":"3786_CR14","unstructured":"Adzynma [summary of product characteristics]. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adzynma-epar-product-information_en.pdf. Accessed 22 Nov 2025."},{"key":"3786_CR15","doi-asserted-by":"crossref","unstructured":"Medicines and Healthcare products Regulatory Agency. MHRA approves first UK treatment for congenital thrombotic thrombocytopenic purpura (cTTP). 2025. https:\/\/www.gov.uk\/government\/news\/mhra-approves-first-uk-treatment-for-congenital-thrombotic-thrombocytopenic-purpura-cttp. Accessed 22 Nov 2025.","DOI":"10.1182\/hematology.2025000759"},{"key":"3786_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/0272989X211028236","volume":"42","author":"L Bojke","year":"2022","unstructured":"Bojke L, Soares MO, Claxton K, et al. Reference case methods for expert elicitation in health care decision making. Med Decis Making. 2022;42:182\u201393.","journal-title":"Med Decis Making"},{"key":"3786_CR17","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jval.2024.07.027","volume":"27","author":"M Soares","year":"2024","unstructured":"Soares M, Colson A, Bojke L, et al. Recommendations on the use of structured expert elicitation protocols for healthcare decision making: a good practices report of an ISPOR Task Force. Value Health. 2024;27:1469\u201378.","journal-title":"Value Health"},{"key":"3786_CR18","unstructured":"University of York. Structured expert elicitation for healthcare decision making: an overview. 2025. https:\/\/www.york.ac.uk\/che\/economic-evaluation\/steer\/. Accessed 20 Mar 2025."},{"key":"3786_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25370","volume":"25","author":"L Bojke","year":"2021","unstructured":"Bojke L, Soares M, Claxton K, et al. Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. Health Technol Assess. 2021;25:1\u2013124.","journal-title":"Health Technol Assess"},{"key":"3786_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2023-188996","volume":"142","author":"M Scully","year":"2023","unstructured":"Scully M, Ortel TL, Yu Z, et al. Recombinant ADAMTS13 for the treatment of acute TTP events in patients with congenital thrombotic thrombocytopenic purpura: results from the phase 3 randomized, controlled, crossover study and the phase 3b continuation study. Blood. 2023;142:692.","journal-title":"Blood"},{"key":"3786_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","volume":"6","author":"A Borogovac","year":"2022","unstructured":"Borogovac A, Reese JA, Gupta S, George JN. Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura. Blood Adv. 2022;6:750\u20139.","journal-title":"Blood Adv"},{"key":"3786_CR22","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","volume":"36","author":"MA Sonneveld","year":"2016","unstructured":"Sonneveld MA, Franco OH, Ikram MA, et al. Von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2016;36:2446\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3786_CR23","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","volume":"104","author":"HA van Dorland","year":"2017","unstructured":"van Dorland HA, Taleghani MM, Sakai K, et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2017;104:2107\u201315.","journal-title":"Haematologica"},{"key":"3786_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1111\/hae.14891","volume":"29","author":"T Chrisentery-Singleton","year":"2023","unstructured":"Chrisentery-Singleton T, Boggio LN, Carcao MD, et al. Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. 2023;29:1638\u201345.","journal-title":"Haemophilia"},{"key":"3786_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2022016044","volume":"140","author":"A Borogovac","year":"2022","unstructured":"Borogovac A, Tarasco E, Kremer Hovinga JA, et al. Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood. 2022;140:785\u20139.","journal-title":"Blood"},{"key":"3786_CR26","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1182\/bloodadvances.2019000959","volume":"3","author":"A Borogovac","year":"2019","unstructured":"Borogovac A, George JN. Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia. Blood Adv. 2019;3:3973\u20136.","journal-title":"Blood Adv"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03786-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:15Z","timestamp":1791576195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03786-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":26,"alternative-id":["3786"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03786-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Annie Berkley and Harneet Kaur are employees of Takeda UK Ltd and Takeda Pharmaceuticals International AG, respectively. Colin Burke and Linda Murphy are employees of Lumanity, which received honoraria or consultation fees from Takeda for this study. Amie Padhiar and Oliver Heard are former employees of Takeda UK Ltd. Mathilde Puls and Harold Wolff are former employees of Lumanity.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in line with Structured Expert Elicitation Resources (STEER), developed by the University of York and based on the York protocol for SEE. Ethics approval was not required, as no patient-level data were collected or shared with the study sponsor. All experts provided informed consent and received an honorarium. Individual responses were anonymized and results were aggregated.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}